105 related articles for article (PubMed ID: 25596034)
21. Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma.
Saulnier Sholler GL; Bond JP; Bergendahl G; Dutta A; Dragon J; Neville K; Ferguson W; Roberts W; Eslin D; Kraveka J; Kaplan J; Mitchell D; Parikh N; Merchant M; Ashikaga T; Hanna G; Lescault PJ; Siniard A; Corneveaux J; Huentelman M; Trent J
Cancer Med; 2015 Jun; 4(6):871-86. PubMed ID: 25720842
[TBL] [Abstract][Full Text] [Related]
22. Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma.
Iyer R; Croucher JL; Chorny M; Mangino JL; Alferiev IS; Levy RJ; Kolla V; Brodeur GM
Cancer Lett; 2015 May; 360(2):205-12. PubMed ID: 25684664
[TBL] [Abstract][Full Text] [Related]
23. Large-scale tracking and classification for automatic analysis of cell migration and proliferation, and experimental optimization of high-throughput screens of neuroblastoma cells.
Harder N; Batra R; Diessl N; Gogolin S; Eils R; Westermann F; König R; Rohr K
Cytometry A; 2015 Jun; 87(6):524-40. PubMed ID: 25630981
[TBL] [Abstract][Full Text] [Related]
24. Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study.
Baronciani D; Depau C; Targhetta C; Derudas D; Culurgioni F; Tandurella I; Latte G; Palmas A; Angelucci E
Hematol Oncol; 2016 Mar; 34(1):17-21. PubMed ID: 25626861
[TBL] [Abstract][Full Text] [Related]
25. Neuroblastoma in Children Under 12 Months in Singapore--15-Year Experience and Outcomes From KKH.
Koh V; Soh SY; Chan MY; Tan AM
Fetal Pediatr Pathol; 2015 Jun; 34(3):155-61. PubMed ID: 25616021
[TBL] [Abstract][Full Text] [Related]
26. Incidence of cancer in children aged 0-14 years in Taiwan, 1996-2010.
Liu YL; Lo WC; Chiang CJ; Yang YW; Lu MY; Hsu WM; Ho WL; Li MJ; Miser JS; Lin DT; Lai MS
Cancer Epidemiol; 2015 Feb; 39(1):21-8. PubMed ID: 25599927
[TBL] [Abstract][Full Text] [Related]
27. Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy.
Gorostegui M; Muñoz JP; Perez-Jaume S; Simao-Rafael M; Larrosa C; Garraus M; Salvador N; Lavarino C; Krauel L; Mañe S; Castañeda A; Mora J
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730688
[TBL] [Abstract][Full Text] [Related]
28. Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes.
Muñoz JP; Larrosa C; Chamorro S; Perez-Jaume S; Simao M; Sanchez-Sierra N; Varo A; Gorostegui M; Castañeda A; Garraus M; Lopez-Miralles S; Mora J
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835531
[TBL] [Abstract][Full Text] [Related]
29. Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report.
Mora J; Castañeda A; Gorostegui M; Varo A; Perez-Jaume S; Simao M; Muñoz JP; Garraus M; Larrosa C; Salvador N; Lavarino C; Krauel L; Mañe S
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37174002
[TBL] [Abstract][Full Text] [Related]
30. MIF/CXCR4 signaling axis contributes to survival, invasion, and drug resistance of metastatic neuroblastoma cells in the bone marrow microenvironment.
Garcia-Gerique L; García M; Garrido-Garcia A; Gómez-González S; Torrebadell M; Prada E; Pascual-Pasto G; Muñoz O; Perez-Jaume S; Lemos I; Salvador N; Vila-Ubach M; Doncel-Requena A; Suñol M; Carcaboso AM; Mora J; Lavarino C
BMC Cancer; 2022 Jun; 22(1):669. PubMed ID: 35715791
[TBL] [Abstract][Full Text] [Related]
31. Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma.
Mora J; Castañeda A; Colombo MC; Gorostegui M; Gomez F; Mañe S; Santa-Maria V; Garraus M; Macias N; Perez-Jaume S; Muñoz O; Muñoz JP; Barber I; Suñol M
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809255
[TBL] [Abstract][Full Text] [Related]
32. The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies.
Mora J; Castañeda A; Flores MA; Santa-María V; Garraus M; Gorostegui M; Simao M; Perez-Jaume S; Mañe S
Front Pharmacol; 2020; 11():575009. PubMed ID: 33324208
[No Abstract] [Full Text] [Related]
33. Neuroblastoma patient-derived cultures are enriched for a mesenchymal gene signature and reflect individual drug response.
Hee E; Wong MK; Tan SH; Choo Z; Kuick CH; Ling S; Yong MH; Jain S; Lian DWQ; Ng EHQ; Yong YFL; Ren MH; Syed Sulaiman N; Low SYY; Chua YW; Syed MF; Lim TKH; Soh SY; Iyer P; Seng MSF; Lam JCM; Tan EEK; Chan MY; Tan AM; Chen Y; Chen Z; Chang KTE; Loh AHP
Cancer Sci; 2020 Oct; 111(10):3780-3792. PubMed ID: 32777141
[TBL] [Abstract][Full Text] [Related]
34. Does Salvage Chemotherapy Regimen Intensity Embark on Clearance of Bone Marrow Neuroblastoma?
Fawzy M; Hamoda A; Elhemaly A; Elkinaai N; Soliman S; Reda H; Elmenawi S; Moussa E
Asian Pac J Cancer Prev; 2019 May; 20(5):1519-1524. PubMed ID: 31128057
[TBL] [Abstract][Full Text] [Related]
35. Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.
Peinemann F; van Dalen EC; Enk H; Berthold F
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD010685. PubMed ID: 28840597
[TBL] [Abstract][Full Text] [Related]
36. Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).
Mora J; Cruz O; Lavarino C; Rios J; Vancells M; Parareda A; Salvador H; Suñol M; Carrasco R; Guillen A; Mañé S; de Torres C
Clin Transl Oncol; 2015 Jul; 17(7):521-9. PubMed ID: 25596034
[TBL] [Abstract][Full Text] [Related]
37. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
Kushner BH; Meyers PA
J Clin Oncol; 2001 Feb; 19(3):870-80. PubMed ID: 11157041
[TBL] [Abstract][Full Text] [Related]
38. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
[TBL] [Abstract][Full Text] [Related]
39. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults.
Kushner BH; Cheung NK; Kramer K; Dunkel IJ; Calleja E; Boulad F
Bone Marrow Transplant; 2001 Sep; 28(6):551-6. PubMed ID: 11607767
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study.
Rujkijyanont P; Photia A; Traivaree C; Monsereenusorn C; Anurathapan U; Seksarn P; Sosothikul D; Techavichit P; Sanpakit K; Phuakpet K; Wiangnon S; Chotsampancharoen T; Chainansamit SO; Kanjanapongkul S; Meekaewkunchorn A; Hongeng S
BMC Cancer; 2019 Oct; 19(1):961. PubMed ID: 31619207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
